glp-1 litigation news today The New York Times spotlighted MEDVi. The FDA had already warned the self-proclaimed 'fastest growing company in history.' GLP-1 Receptor Agonist Litigation: MDL

Potential Side Effects and Digestive Changes The most common adverse effects of Wegovy involve the gastrointestinal system, with nausea, diarrhoea, vomiting, constipation, and abdominal pain reported in clinical trials, as detailed in the MHRA-approved SmPC

We will continue to scrutinise the data to see whether abnormal blood test results such as having pre-diabetes might predict a better response to exenatide, and whether there were more of these people in the earlier, smaller trials in which we found positive overall effects. The trial was supported by the UCL Comprehensive Clinical Trials Unit (UCL CCTU), the National Institute for Health and Care Research (NIHR), UCLH Biomedical Research Centre and the NIHR UCLH Clinical Research Facility

For instance, in December 2025, a bipartisan coalition of 35 attorneys general wrote to Meta alleging the company was permitting companies to advertise weight-loss products with deceptive, AI-generated before-after comparison photos

In fact, 96% of those using Nutracheck alongside GLP-1s intend to continue using Nutracheck once they stop the medication

[DOI] [PMC free article] [PubMed] [Google Scholar] 2.Drucker D.J